A US National Eye Institute Phase III clinical trial of Lucentis in diabetic macular edema has demonstrated a beneficial effect in combination with laser therapy. While Lucentis already dominates the macular degeneration market with a 95% global market share in 2009, Datamonitor sees potential for the drug to gain approval in the untapped diabetic macular edema market.
Encouraging trial data presented at this year's American Diabetes Association meeting reveal that Roche's Lucentis significantly improves visual acuity among patients with diabetic macular edema. If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market. Nevertheless, off-label use of Avastin may temper sales.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions